Soluble ST2 - Analytical considerations

American Journal of Cardiology

Volumn 115, Issue 7, 2015, Pages 8B-21B

  Mueller, Thomas ^a   Jaffe, Allan S ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; MEMBRANE RECEPTOR; SUPPRESSION OF TUMORIGENICITY 2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN;

ARTICLE; ASSAY; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PRESAGE ST2 ASSAY; PRIORITY JOURNAL; REFERENCE VALUE; STANDARDIZATION; BLOOD; HEART DISEASE; PROGNOSIS; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; HEART DISEASES; HUMANS; PROGNOSIS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84924977569     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.01.035     Document Type: Review

References (158)

1. E.O. Weinberg ST2 protein in heart disease: from discovery to mechanisms and prognostic value Biomark Med 3 2009 495 511
2. F.Y. Liew, N.I. Pitman, and I.B. McInnes Disease-associated functions of IL-33: the new kid in the IL-1 family Nat Rev Immunol 10 2010 103 110
3. A.M. Miller, and F.Y. Liew The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease Pharmacol Ther 131 2011 179 186
4. T. Mueller, and B. Dieplinger The Presage ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2 Expert Rev Mol Diagn 13 2013 13 30
5. D.O. Villarreal, and D.B. Weiner Interleukin 33: a switch-hitting cytokine Curr Opin Immunol 28C 2014 102 106
6. D. Pascual-Figal, and J.L. Januzzi Jr. The biology of ST2: the international ST2 consensus panel Am J Cardiol 115 suppl 2015 3B 7B
7. K. Kuroiwa, H. Li, K. Tago, H. Iwahana, K. Yanagisawa, N. Komatsu, K. Oshikawa, Y. Sugiyama, T. Arai, and S.I. Tominaga Construction of ELISA system to quantify human ST2 protein in sera of patients Hybridoma 19 2000 151 159
8. A.M. Brown, A.H. Wu, P. Clopton, J.L. Robey, and J.E. Hollander ST2 in emergency department chest pain patients with potential acute coronary syndromes Ann Emerg Med 50 2007 153 158
9. S.J. Aldous, A.M. Richards, R. Troughton, and M. Than ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain J Card Fail 18 2012 304 310
10. J.L. Januzzi Jr., W.F. Peacock, A.S. Maisel, C.U. Chae, R.L. Jesse, A.L. Baggish, M. O'Donoghue, R. Sakhuja, A.A. Chen, R.R. van Kimmenade, K.B. Lewandrowski, D.M. Lloyd-Jones, and A.H. Wu Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study J Am Coll Cardiol 50 2007 607 613
11. A. Martinez-Rumayor, C.A. Camargo, S.M. Green, A.L. Baggish, M. O'Donoghue, and J.L. Januzzi Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease Am J Clin Pathol 130 2008 578 584
12. S.U. Rehman, A. Martinez-Rumayor, T. Mueller, and J.L. Januzzi Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study Clin Chim Acta 392 2008 41 45
13. B. Dieplinger, A. Gegenhuber, M. Haltmayer, and T. Mueller Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath Heart 95 2009 1508 1513
14. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea Circ Heart Fail 2 2009 311 319
15. B. Dieplinger, A. Gegenhuber, G. Kaar, W. Poelz, M. Haltmayer, and T. Mueller Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department Clin Biochem 43 2010 714 719
16. J.L. Januzzi Jr., S. Rehman, T. Mueller, R.R. van Kimmenade, and D.M. Lloyd-Jones Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients Clin Chem 56 2010 1814 1821
17. T. Socrates, C. deFilippi, T. Reichlin, R. Twerenbold, T. Breidhardt, M. Noveanu, M. Potocki, M. Reiter, N. Arenja, C. Heinisch, J. Meissner, C. Jaeger, R. Christenson, and C. Mueller Interleukin family member ST2 and mortality in acute dyspnoea J Intern Med 268 2010 493 500
18. K.B. Shah, W.J. Kop, R.H. Christenson, D.B. Diercks, S. Henderson, K. Hanson, S.Y. Li, and C.R. deFilippi Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction Clin Chem 57 2011 874 882
19. J.L. Benoit, C.W. Hicks, R.S. Engineer, K.W. Hart, C.J. Lindsell, and W.F. Peacock ST2 in emergency department patients with noncardiac dyspnea Acad Emerg Med 20 2013 1207 1210
20. K. Sahlander, K. Larsson, and L. Palmberg Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities J Occup Environ Med 52 2010 214 218
21. Y.C. Wang, C.C. Yu, F.C. Chiu, C.T. Tsai, L.P. Lai, J.J. Hwang, and J.L. Lin Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients J Card Fail 19 2013 163 168
22. D.B. Ojji, L.H. Opie, S. Lecour, L. Lacerda, O. Adeyemi, and K.J. Sliwa Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients Clin Hypertens (Greenwich) 15 2013 899 904
23. J.E. Ho, M.G. Larson, A. Ghorbani, S. Cheng, R.S. Vasan, T.J. Wang, and J.L. Januzzi Jr. Soluble ST2 predicts elevated SBP in the community J Hypertens 31 2013 1431 1436
24. D.B. Ojji, L.H. Opie, S. Lecour, L. Lacerda, O.M. Adeyemi, and K. Sliwa The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects J Hum Hypertens 28 2014 432 437
25. G. Carlomagno, G. Messalli, R.M. Melillo, A.A. Stanziola, C. Visciano, V. Mercurio, M. Imbriaco, S. Ghio, M. Sofia, D. Bonaduce, and S. Fazio Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension Int J Cardiol 168 2013 1545 1547
26. A. Chida, H. Sato, M. Shintani, T. Nakayama, Y. Kawamura, Y. Furutani, K. Inai, T. Saji, R. Matsuoka, S. Nonoyama, and T. Nakanishi Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension Circ J 78 2014 436 442
27. S. Willems, P.H. Quax, G.J. de Borst, J.P. de Vries, F.L. Moll, D.P. de Kleijn, I.E. Hoefer, and G. Pasterkamp Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis Atherosclerosis 231 2013 48 53
28. S. Willems, J.W. Sels, S. Flier, D. Versteeg, W.F. Buhre, D.P. de Kleijn, I.E. Hoefer, and G. Pasterkamp Temporal changes of soluble ST2 after cardiovascular interventions Eur J Clin Invest 43 2013 113 120
29. A. Caporali, M. Meloni, A.M. Miller, K. Vierlinger, A. Cardinali, G. Spinetti, A. Nailor, E. Faglia, S. Losa, A. Gotti, O. Fortunato, T. Mitic, M. Hofner, C. Noehammer, P. Madeddu, and C. Emanueli Soluble ST2 is regulated by p75 neurotrophin receptor and predicts mortality in diabetic patients with critical limb ischemia Arterioscler Thromb Vasc Biol 32 2012 e149 e160
30. D. Talabot-Ayer, T. McKee, P. Gindre, S. Bas, D.L. Baeten, C. Gabay, and G. Palmer Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis Joint Bone Spine 79 2012 32 37
31. Y.S. Hong, S.J. Moon, Y.B. Joo, C.H. Jeon, M.L. Cho, J.H. Ju, H.J. Oh, Y.J. Heo, S.H. Park, H.Y. Kim, and J.K. Min Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis J Korean Med Sci 26 2011 1132 1139
32. S. Tang, H. Huang, F. Hu, W. Zhou, J. Guo, H. Jiang, R. Mu, and Z. Li Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis Clin Dev Immunol 2013 2013 985301
33. X.L. Li, T.T. Lin, C.Y. Qi, L. Yuan, L.P. Xia, H. Shen, and J. Lu Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor J Investig Med 61 2013 848 851
34. A. Awada, C. Nicaise, S. Ena, L. Schandéné, J. Rasschaert, I. Popescu, V. Gangji, and M.S. Soyfoo Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome Ann Rheum Dis 73 2014 1259 1263
35. L. Zhao, L. Yao, L. Yuan, L. Xia, H. Shen, and J. Lu Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome Cytokine 64 2013 22 24
36. M.Y. Mok, F.P. Huang, W.K. Ip, Y. Lo, F.Y. Wong, E.Y. Chan, K.F. Lam, and D. Xu Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus Rheumatology (Oxford) 49 2010 520 527
37. K. Kuroiwa, T. Arai, H. Okazaki, S. Minota, and S. Tominaga Identification of human ST2 protein in the sera of patients with autoimmune diseases Biochem Biophys Res Commun 284 2001 1104 1108
38. D.J. Kim, S.Y. Baek, M.K. Park, K.S. Park, J.H. Lee, S.H. Park, H.Y. Kim, and S.K. Kwok Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease J Korean Med Sci 28 2013 1145 1153
39. L. Yuan, L. Yao, L. Zhao, L. Xia, H. Shen, and J. Lu Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis Clin Exp Rheumatol 31 2013 428 432
40. M. Rechardt, R. Shiri, S. Matikainen, E. Viikari-Juntura, J. Karppinen, and H. Alenius Soluble IL-1RII and IL-18 are associated with incipient upper extremity soft tissue disorders Cytokine 54 2011 149 153
41. M.T. Vander Lugt, T.M. Braun, S. Hanash, J. Ritz, V.T. Ho, J.H. Antin, Q. Zhang, C.H. Wong, H. Wang, A. Chin, A. Gomez, A.C. Harris, J.E. Levine, S.W. Choi, D. Couriel, P. Reddy, J.L. Ferrara, and S. Paczesny ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death N Engl J Med 369 2013 529 539
42. J. Gillibert-Duplantier, B. Duthey, V. Sisirak, D. Salaün, T. Gargi, O. Trédan, P. Finetti, F. Bertucci, D. Birnbaum, N. Bendriss-Vermare, and A. Badache Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis Oncogene 31 2012 3516 3524
43. D.P. Lu, X.Y. Zhou, L.T. Yao, C.G. Liu, W. Ma, F. Jin, and Y.F. Wu Serum soluble ST2 is associated with ER-positive breast cancer BMC Cancer 14 2014 198
44. H. Sawaya, I.A. Sebag, J.C. Plana, J.L. Januzzi, B. Ky, T.C. Tan, V. Cohen, J. Banchs, J.R. Carver, S.E. Wiegers, R.P. Martin, M.H. Picard, R.E. Gerszten, E.F. Halpern, J. Passeri, I. Kuter, and M. Scherrer-Crosbie Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab Circ Cardiovasc Imaging 5 2012 596 603
45. D. Bergis, V. Kassis, A. Ranglack, V. Koeberle, A. Piiper, B. Kronenberger, S. Zeuzem, O. Waidmann, and H.H. Radeke High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma Transl Oncol 6 2013 311 318
46. K. Oshikawa, K. Yanagisawa, S. Ohno, S. Tominaga, and Y. Sugiyama Expression of ST2 in helper T lymphocytes of malignant pleural effusions Am J Respir Crit Care Med 165 2002 1005 1009
47. K.S. Lee, H.R. Kim, S. Kwak, K.H. Choi, J.H. Cho, Y.J. Lee, M.K. Lee, J.H. Lee, S.D. Park, and D.S. Park Association between elevated pleural interleukin-33 levels and tuberculous pleurisy Ann Lab Med 33 2013 45 51
48. E.O. Weinberg, M. Shimpo, G.W. De Keulenaer, C. MacGillivray, S. Tominaga, S.D. Solomon, J.L. Rouleau, and R.T. Lee Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction Circulation 106 2002 2961 2966
49. O.S. Dhillon, H.K. Narayan, S.Q. Khan, D. Kelly, P.A. Quinn, I.B. Squire, J.E. Davies, and L.L. Ng Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 167 2013 2182 2188
50. M. Shimpo, D.A. Morrow, E.O. Weinberg, M.S. Sabatine, S.A. Murphy, E.M. Antman, and R.T. Lee Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction Circulation 109 2004 2186 2190
51. M.S. Sabatine, D.A. Morrow, L.J. Higgins, C. MacGillivray, W. Guo, C. Bode, N. Rifai, C.P. Cannon, R.E. Gerszten, and R.T. Lee Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction Circulation 117 2008 1936 1944
52. R.A. Weir, A.M. Miller, G.E. Murphy, S. Clements, T. Steedman, J.M. Connell, I.B. McInnes, H.J. Dargie, and J.J. McMurray Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction J Am Coll Cardiol 55 2010 243 250
53. K. Zhang, X.C. Zhang, Y.H. Mi, and J. Liu Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction Chin Med J 126 2013 3628 3631
54. S. Demyanets, W.S. Speidl, I. Tentzeris, R. Jarai, K.M. Katsaros, S. Farhan, K.A. Krychtiuk, A. Wonnerth, T.W. Weiss, K. Huber, and J. Wojta Soluble ST2 and Interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome PLoS One 9 2014 e95055
55. O.S. Dhillon, H.K. Narayan, P.A. Quinn, I.B. Squire, J.E. Davies, and L.L. Ng Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP Am Heart J 161 2011 1163 1170
56. K.M. Eggers, P.W. Armstrong, R.M. Califf, M.L. Simoons, P. Venge, L. Wallentin, and S.K. James ST2 and mortality in non-ST-segment elevation acute coronary syndrome Am Heart J 159 2010 788 794
57. P. Kohli, M.P. Bonaca, R. Kakkar, A.Y. Kudinova, B.M. Scirica, M.S. Sabatine, S.A. Murphy, E. Braunwald, R.T. Lee, and D.A. Morrow Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial Clin Chem 58 2012 257 266
58. R.G. O'Malley, M.P. Bonaca, B.M. Scirica, S.A. Murphy, P. Jarolim, M.S. Sabatine, E. Braunwald, and D.A. Morrow Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency with Ranolazine for Less ischemia in non-ST-elevation acute coronary syndromes-Thrombolysis in myocardial infarction 36) J Am Coll Cardiol 63 2014 1644 1653
59. B. Dieplinger, M. Egger, M. Haltmayer, M.E. Kleber, H. Scharnagl, G. Silbernagel, R.A. de Boer, M. Maerz, and T. Mueller Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease - results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study Clin Chem 60 2014 530 540
60. T. Mueller, B. Dieplinger, A. Gegenhuber, W. Poelz, R. Pacher, and M. Haltmayer Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure Clin Chem 54 2008 752 756
61. S.U. Rehman, T. Mueller, and J.L. Januzzi Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure J Am Coll Cardiol 52 2008 1458 1465
62. S. Boisot, J. Beede, S. Isakson, A. Chiu, P. Clopton, J. Januzzi, A.S. Maisel, and R.L. Fitzgerald Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure Card Fail 14 2008 732 738
63. A. Bayes-Genis, D. Pascual-Figal, J.L. Januzzi, A. Maisel, T. Casas, M. Valdés Chávarri, and J. Ordóñez-Llanos Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure Rev Esp Cardiol 63 2010 1171 1178
64. S. Manzano-Fernández, T. Mueller, D. Pascual-Figal, Q.A. Truong, and J.L. Januzzi Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction Am J Cardiol 107 2011 259 267
65. Q. Henry-Okafor, S.P. Collins, C.A. Jenkins, K.F. Miller, D.J. Maron, A.J. Naftilan, N. Weintraub, G.J. Fermann, J. McPherson, S. Menon, D.B. Sawyer, and A.B. Storrow Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes Open Biomark J 2012 2012 1 8
66. D.A. Pascual-Figal, S. Manzano-Fernández, M. Boronat, T. Casas, I.P. Garrido, J.C. Bonaque, F. Pastor-Perez, M. Valdés, and J.L. Januzzi Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure Eur J Heart Fail 13 2011 718 725
67. S. Manzano-Fernández, J.L. Januzzi, F.J. Pastor-Pérez, J.C. Bonaque-González, M. Boronat-Garcia, D.A. Pascual-Figal, S. Montalban-Larrea, M. Navarro-Peñalver, J.M. Andreu-Cayuelas, and M. Valdés Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure Cardiology 122 2012 158 166
68. J. Lassus, E. Gayat, C. Mueller, W.F. Peacock, J. Spinar, V.P. Harjola, R. van Kimmenade, A. Pathak, T. Mueller, S. Disomma, M. Metra, D. Pascual-Figal, S. Laribi, D. Logeart, S. Nouira, N. Sato, M. Potocki, J. Parenica, C. Collet, A. Cohen-Solal, J.L. Januzzi Jr., A. Mebazaa for the GREAT-Network Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study Int J Cardiol 168 2013 2186 2194
69. T. Breidthardt, C. Balmelli, R. Twerenbold, T. Mosimann, J. Espinola, P. Haaf, G. Thalmann, B. Moehring, M. Mueller, B. Meller, T. Reichlin, K. Murray, R. Ziller, P. Benkert, S. Osswald, and C. Mueller Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance J Card Fail 19 2013 821 828
70. P.A. Scott, P.A. Townsend, L.L. Ng, M. Zeb, S. Harris, P.J. Roderick, N.P. Curzen, and J.M. Morgan Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers Europace 13 2011 1419 1427
71. E.O. Weinberg, M. Shimpo, S. Hurwitz, S. Tominaga, J.L. Rouleau, and R.T. Lee Identification of serum soluble ST2 receptor as a novel heart failure biomarker Circulation 107 2003 721 726
72. D.A. Pascual-Figal, J. Ordoñez-Llanos, P.L. Tornel, R. Vázquez, T. Puig, M. Valdés, J. Cinca, A.B. de Luna, A. Bayes-Genis MUSIC Investigators Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 2009 2174 2179
73. K. Wojtczak-Soska, T. Pietrucha, A. Sakowicz, and M. Lelonek Soluble ST2 protein in chronic heart failure is independent of traditional factors Arch Med Sci 9 2013 21 26
74. K. Wojtczak-Soska, A. Sakowicz, T. Pietrucha, and M. Lelonek Soluble ST2 protein in the short-term prognosis after hospitalization in chronic systolic heart failure Kardiol Pol 72 2014 725 734
75. H.F. Zhang, S.L. Xie, Y.X. Chen, J.T. Mai, J.F. Wang, W.L. Zhu, and L.G. Zhu Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress J Transl Med 10 2012 120
76. C. Caselli, A. D'Amico, R. Ragusa, R. Caruso, T. Prescimone, M. Cabiati, S. Nonini, P. Marraccini, S. Del Ry, M.G. Trivella, O. Parodi, and D. Giannessi IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? Mediators Inflamm 2013 2013 498703
77. L.B. Daniels, P. Clopton, N. Iqbal, K. Tran, and A.S. Maisel Association of ST2 levels with cardiac structure and function and mortality in outpatients Am Heart J 160 2010 721 728
78. B. Ky, B. French, K. McCloskey, J.E. Rame, E. McIntosh, P. Shahi, D.L. Dries, W.H. Tang, A.H. Wu, J.C. Fang, R. Boxer, N.K. Sweitzer, W.C. Levy, L.R. Goldberg, M. Jessup, and T.P. Cappola High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure Circ Heart Fail 4 2011 180 187
79. B. Ky, B. French, W.C. Levy, N.K. Sweitzer, J.C. Fang, A.H. Wu, L.R. Goldberg, M. Jessup, and T.P. Cappola Multiple biomarkers for risk prediction in chronic heart failure Circ Heart Fail 5 2012 183 190
80. A. Bayes-Genis, M. de Antonio, A. Galán, H. Sanz, A. Urrutia, R. Cabanes, L. Cano, B. González, C. Díez, T. Pascual, R. Elosúa, and J. Lupón Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure Eur J Heart Fail 14 2012 32 38
81. K. Broch, T. Ueland, S.H. Nymo, J. Kjekshus, J. Hulthe, P. Muntendam, J.J. McMurray, J. Wikstrand, J.G. Cleland, P. Aukrust, and L. Gullestad Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology Eur J Heart Fail 14 2012 268 277
82. J. Lupón, M. de Antonio, A. Galán, J. Vila, E. Zamora, A. Urrutia, and A. Bayes-Genis Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment Mayo Clin Proc 88 2013 234 243
83. R. Santhanakrishnan, J.P. Chong, T.P. Ng, L.H. Ling, D. Sim, K.T. Leong, P.S. Yeo, H.Y. Ong, F. Jaufeerally, R. Wong, P. Chai, A.F. Low, A.M. Richards, and C.S. Lam Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction Eur J Heart Fail 14 2012 1338 1347
84. A. Bayes-Genis, E. Zamora, M. de Antonio, A. Galán, J. Vila, A. Urrutia, C. Díez, R. Coll, S. Altimir, and J. Lupón Soluble ST2 serum concentration and renal function in heart failure J Card Fail 19 2013 768 775
85. G.M. Felker, M. Fiuzat, V. Thompson, L.K. Shaw, M.L. Neely, K.F. Adams, D.J. Whellan, M.P. Donahue, T. Ahmad, D.W. Kitzman, I.L. Piña, F. Zannad, W.E. Kraus, and C.M. O'Connor Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes Circ Heart Fail 6 2013 1172 1179
86. H.K. Gaggin, S. Motiwala, A. Bhardwaj, K.A. Parks, and J.L. Januzzi Jr. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure Circ Heart Fail 6 2013 1206 1213
87. A. Bayes-Genis, M. de Antonio, J. Vila, J. Peñafiel, A. Galán, J. Barallat, E. Zamora, A. Urrutia, and J. Lupón Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3 J Am Coll Cardiol 63 2014 158 166
88. H.K. Gaggin, J. Szymonifka, A. Bhardwaj, A. Belcher, B. De Berardinis, S. Motiwala, T.J. Wang, and J.L. Januzzi Jr. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure JACC Heart Fail 2 2014 65 72
89. D. Gruson, T. Lepoutre, S.A. Ahn, and M.F. Rousseau Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction Int J Cardiol 172 2014 e250 e252
90. I.S. Anand, T.S. Rector, M. Kuskowski, J. Snider, and J.N. Cohn Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial Circ Heart Fail 7 2014 418 426
91. J. Bartunek, L. Delrue, F. Van Durme, O. Muller, F. Casselman, B. De Wiest, R. Croes, S. Verstreken, M. Goethals, H. de Raedt, J. Sarma, L. Joseph, M. Vanderheyden, and E.O. Weinberg Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load J Am Coll Cardiol 52 2008 2166 2174
92. A. Galeone, A. Lessana, E. Mascolo, F. Di Serio, N. Marraudino, F. Laborde, and D. Paparella Interleukin-1 receptor-related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation Thorac Cardiovasc Surg 62 2014 47 51
93. R. Dworakowski, O. Wendler, A. Bhan, L. Smith, P. Pearson, E. Alcock, K. Rajagopal, B. Brickham, T. Dew, J. Byrne, M.J. Monaghan, R. Sherwood, A.M. Shah, and P.A. MacCarthy Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction Heart 98 2012 1641 1646
94. T. Szerafin, M. Brunner, A. Horváth, L. Szentgyörgyi, B. Moser, G. Boltz-Nitulescu, A. Péterffy, K. Hoetzenecker, B. Steinlechner, E. Wolner, and H.J. Ankersmit Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions Clin Lab 51 2005 657 663
95. T. Szerafin, T. Niederpold, A. Mangold, K. Hoetzenecker, S. Hacker, G. Roth, M. Lichtenauer, M. Dworschak, E. Wolner, and H.J. Ankersmit Secretion of soluble ST2-possible explanation for systemic immunosuppression after heart surgery Thorac Cardiovasc Surg 57 2009 25 29
96. J.L. Januzzi, B.D. Horne, S.A. Moore, O. Galenko, G.L. Snow, K.D. Brunisholz, J.B. Muhlestein, R. Alharethi, J.F. Carlquist, D. Budge, K. Rasmussen, and A.G. Kfoury Interleukin receptor family member ST2 concentrations in patients following heart transplantation Biomarkers 18 2013 250 256
97. D.A. Pascual-Figal, I.P. Garrido, R. Blanco, A. Minguela, A. Lax, J. Ordoñez-Llanos, A. Bayes-Genis, M. Valdés, S.A. Moore, and J.L. Januzzi Soluble ST2 is a marker for acute cardiac allograft rejection Ann Thorac Surg 92 2011 2118 2124
98. Y.Z. Sato, D.P. Molkara, L.B. Daniels, A.H. Tremoulet, C. Shimizu, J.T. Kanegaye, B.M. Best, J.V. Snider, J.R. Frazer, A. Maisel, and J.C. Burns Cardiovascular biomarkers in acute Kawasaki disease Int J Cardiol 164 2013 58 63
99. M. Brunner, C. Krenn, G. Roth, B. Moser, M. Dworschak, E. Jensen-Jarolim, A. Spittler, T. Sautner, N. Bonaros, E. Wolner, G. Boltz-Nitulescu, and H.J. Ankersmit Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma Intensive Care Med 30 2004 1468 1473
100. J.J. Hoogerwerf, M.W. Tanck, M.A. van Zoelen, X. Wittebole, P.F. Laterre, and T. van der Poll Soluble ST2 plasma concentrations predict mortality in severe sepsis Intensive Care Med 36 2010 630 637
101. J.C. Alves-Filho, F. Sônego, F.O. Souto, A. Freitas, W.A. Verri Jr., M. Auxiliadora-Martins, A. Basile-Filho, A.N. McKenzie, D. Xu, F.Q. Cunha, and F.Y. Liew Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection Nat Med 16 2010 708 712
102. J. Parenica, J. Malaska, J. Jarkovsky, J. Lipkova, M. Dastych, K. Helanova, J. Litzman, J. Tomandl, S. Littnerova, J. Sevcikova, R. Gal, P. Sevcik, J. Spinar, and M.P. Goldbergova Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality Exp Clin Cardiol 17 2012 205 209
103. B. Dieplinger, J.L. Januzzi Jr., M. Steinmair, C. Gabriel, W. Poelz, M. Haltmayer, and T. Mueller Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay Clin Chim Acta 409 2009 33 40
104. E.K. Bajwa, J.A. Volk, D.C. Christiani, R.S. Harris, M.A. Matthay, B.T. Thompson, J.L. Januzzi National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome Crit Care Med 41 2013 2521 2531
105. B. Dieplinger, M. Egger, W. Koehler, F. Firlinger, W. Poelz, K. Lenz, M. Haltmayer, and T. Mueller Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit - the Linz Intensive Care Unit (LICU) study Clin Chim Acta 413 2012 587 593
106. J.L. Zilinski, R.V. Shah, H.K. Gaggin, M.L. Gantzer, T.J. Wang, and J.L. Januzzi Jr. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy Crit Care 16 2012 R135
107. E.E. Coglianese, M.G. Larson, R.S. Vasan, J.E. Ho, A. Ghorbani, E.L. McCabe, S. Cheng, M.G. Fradley, D. Kretschman, W. Gao, G. O'Connor, T.J. Wang, and J.L. Januzzi Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study Clin Chem 58 2012 1673 1681
108. A.M. Miller, D. Purves, A. McConnachie, D.L. Asquith, G.D. Batty, H. Burns, J. Cavanagh, I. Ford, J.S. McLean, C.J. Packard, P.G. Shiels, H. Turner, Y.N. Velupillai, K.A. Deans, P. Welsh, I.B. McInnes, and N. Sattar Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One 7 2012 e47830
109. E. Fousteris, A. Melidonis, G. Panoutsopoulos, K. Tzirogiannis, S. Foussas, A. Theodosis-Georgilas, S. Tzerefos, S. Matsagos, E. Boutati, T. Economopoulos, G. Dimitriadis, and S. Raptis Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction Cardiovasc Diabetol 10 2011 101
110. E. Fousteris, A. Theodosis-Georgilas, S. Chantanis, P. Spiropoulou, S. Mavrogeni, T. Economopoulos, E. Boutati, G. Dimitriadis, S. Foussas, and A. Melidonis Head-to-head comparison of 2 inflammatory biomarkers for the long-term prediction of left ventricular diastolic dysfunction in type 2 diabetes patients: soluble ST2 versus hs-CRP Int J Cardiol 174 2014 811 812
111. J.F. Wagenaar, M.H. Gasem, M.G. Goris, M. Leeflang, R.A. Hartskeerl, T. van der Poll, C. van 't Veer, and E.C. van Gorp Soluble ST2 levels are associated with bleeding in patients with severe leptospirosis Plos Negl Trop Dis 3 2009 e453
112. F.I. Calò Carducci, L.R. Aufiero, L. Folgori, A.C. Vittucci, D. Amodio, M. De Luca, G. Li Pira, A. Bergamini, G. Pontrelli, A. Finocchi, and P. D'Argenio Serum soluble ST2 as diagnostic marker of systemic inflammatory reactive syndrome of bacterial etiology in children Pediatr Infect Dis J 33 2014 199 203
113. A. Becerra, R.V. Warke, N. de Bosch, A.L. Rothman, and I. Bosch Elevated levels of soluble ST2 protein in dengue virus infected patients Cytokine 41 2008 114 120
114. C.D. Guerrero, A.F. Arrieta, N.D. Ramirez, L.S. Rodríguez, R. Vega, I. Bosch, J.A. Rodríguez, C.F. Narváez, and D.M. Salgado High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue Cytokine 61 2013 766 771
115. T. Miyagaki, M. Sugaya, H. Yokobayashi, T. Kato, H. Ohmatsu, H. Fujita, H. Saeki, Y. Kikuchi, T. Tamaki, and S. Sato High levels of soluble ST2 and low levels of IL-33 in sera of patients with HIV infection J Invest Dermatol 131 2011 794 796
116. A. Bradley-Stewart, L. Jolly, W. Adamson, R. Gunson, C. Frew-Gillespie, K. Templeton, C. Aitken, W. Carman, S. Cameron, and C. McSharry Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09 J Clin Virol 58 2013 100 107
117. M. Mildner, A. Storka, M. Lichtenauer, V. Mlitz, M. Ghannadan, K. Hoetzenecker, S. Nickl, B. Dome, E. Tschachler, and H.J. Ankersmit Primary sources and immunological prerequisites for sST2 secretion in humans Cardiovasc Res 87 2010 769 777
118. C.J. Beltrán, L.E. Núñez, D. Díaz-Jiménez, N. Farfan, E. Candia, C. Heine, F. López, M.J. González, R. Quera, and M.A. Hermoso Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease Inflamm Bowel Dis 16 2010 1097 1107
119. L. Pastorelli, R.R. Garg, S.B. Hoang, L. Spina, B. Mattioli, M. Scarpa, C. Fiocchi, M. Vecchi, and T.T. Pizarro Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis Proc Natl Acad Sci U S A 107 2010 8017 8022
120. D. Díaz-Jiménez, L.E. Núñez, C.J. Beltrán, E. Candia, C. Suazo, M. Alvarez-Lobos, M.J. González, M.A. Hermoso, and R. Quera Soluble ST2: a new and promising activity marker in ulcerative colitis World J Gastroenterol 17 2011 2181 2190
121. M. Shimizu, A. Matsuda, K. Yanagisawa, T. Hirota, M. Akahoshi, N. Inomata, K. Ebe, K. Tanaka, H. Sugiura, K. Nakashima, M. Tamari, N. Takahashi, K. Obara, T. Enomoto, Y. Okayama, P.S. Gao, S.K. Huang, S. Tominaga, Z. Ikezawa, and T. Shirakawa Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis Hum Mol Genet 14 2005 2919 2927
122. K. Wakatabi, M. Komine, J. Meephansan, Y. Matsuyama, H. Tsuda, S. Tominaga, and M. Ohtsuki The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid Eur J Dermatol 22 2012 333 336
123. G.A. Roth, M. Zimmermann, B.A. Lubsczyk, J. Pilz, P. Faybik, H. Hetz, S. Hacker, A. Mangold, A. Bacher, C.G. Krenn, and H.J. Ankersmit Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure J Surg Res 163 2010 e79 e83
124. J. Wang, Y. Cai, H. Ji, J. Feng, D.A. Ayana, J. Niu, and Y. Jiang Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B J Interferon Cytokine Res 32 2012 248 253
125. J. Wang, P. Zhao, H. Guo, X. Sun, Z. Jiang, L. Xu, J. Feng, J. Niu, and Y. Jiang Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C Mediators Inflamm 2012 2012 819636
126. C.Y. Lin, C.M. Pfluger, R.D. Henderson, and P.A. McCombe Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis J Neuroimmunol 249 2012 93 95
127. M. Kanda, H. Ohto-Ozaki, K. Kuroiwa, S. Tominaga, E. Watanabe, and H. Iwahana Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage Acta Neurol Scand 113 2006 327 333
128. R. Ouziel, T. Gustot, C. Moreno, M. Arvanitakis, D. Degré, E. Trépo, E. Quertinmont, V. Vercruysse, P. Demetter, O. Le Moine, A.N. McKenzie, M. Delhaye, J. Devière, and A. Lemmers The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice Am J Pathol 180 2012 2330 2339
129. I. Granne, J.H. Southcombe, J.V. Snider, D.S. Tannetta, T. Child, C.W. Redman, and I.L. Sargent ST2 and IL-33 in pregnancy and pre-eclampsia PLoS One 6 2011 e24463
130. T. Stampalija, T. Chaiworapongsa, R. Romero, P. Chaemsaithong, S.J. Korzeniewski, A.G. Schwartz, E.M. Ferrazzi, Z. Dong, and S.S. Hassan Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia J Matern Fetal Neonatal Med 26 2013 1359 1370
131. T.J. Kaitu'u-Lino, L. Tuohey, and S. Tong Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage J Reprod Immunol 95 2012 46 49
132. J.H. Southcombe, N. Lédée, S. Perrier d'Hauterive, K. Turner, T. Child, J.V. Snider, C.W. Redman, I.L. Sargent, and I. Granne Detection of soluble ST2 in human follicular fluid and luteinized granulosa cells PLoS One 8 2013 e74385
133. K. Oshikawa, K. Kuroiwa, K. Tago, H. Iwahana, K. Yanagisawa, S. Ohno, S.I. Tominaga, and Y. Sugiyama Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation Am J Respir Crit Care Med 164 2001 277 281
134. M. Ali, G. Zhang, W.R. Thomas, C.J. McLean, J.A. Bizzintino, I.A. Laing, A.C. Martin, J. Goldblatt, P.N. Le Souëf, and C.M. Hayden Investigations into the role of ST2 in acute asthma in children Tissue Antigens 73 2009 206 212
135. T. Tunc, F. Cekmez, S. Yildirim, O. Bulut, Z. Ince, M. Saldir, G. Aydemir, H. Yaman, and A. Coban Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia Pediatr Res 75 2014 788 792
136. S. Hacker, C. Lambers, A. Pollreisz, K. Hoetzenecker, M. Lichtenauer, A. Mangold, T. Niederpold, A. Hacker, G. Lang, M. Dworschak, T. Vukovich, C. Gerner, W. Klepetko, and H.J. Ankersmit Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD J Clin Lab Anal 23 2009 372 379
137. Y. Tang, Y. Guan, Y. Liu, J. Sun, L. Xu, and Y. Jiang The role of the serum IL-33/sST2 axis and inflammatory cytokines in chronic obstructive pulmonary disease J Interferon Cytokine Res 34 2014 162 168
138. S. Tajima, K. Oshikawa, S. Tominaga, and Y. Sugiyama The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis Chest 124 2003 1206 1214
139. K. Oshikawa, K. Kuroiwa, T. Tokunaga, T. Kato, S.I. Hagihara, S.I. Tominaga, and Y. Sugiyama Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid Respir Med 95 2001 532 533
140. Y.S. Bao, S.P. Na, P. Zhang, X.B. Jia, R.C. Liu, C.Y. Yu, S.H. Mu, and R.J. Xie Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease J Clin Immunol 32 2012 587 594
141. S. Bruneau, L. Le Berre, C. Hervé, A. Valanciuté, M. Kamal, J. Naulet, L. Tesson, Y. Foucher, J.P. Soulillou, D. Sahali, and J. Dantal Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation Am J Kidney Dis 54 2009 522 532
142. A. Thierry, S. Giraud, A. Robin, A. Barra, F. Bridoux, V. Ameteau, T. Hauet, J.P. Girard, G. Touchard, J.M. Gombert, and A. Herbelin The alarmin concept applied to human renal transplantation: evidence for a differential implication of HMGB1 and IL-33 PLoS One 9 2014 e88742
143. L.Q. Chen, J.A. de Lemos, S.R. Das, C.R. Ayers, and A. Rohatgi Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study Clin Chem 59 2013 536 546
144. F.S. Apple, L.M. Steffen, L.A. Pearce, M.M. Murakami, and R.V. Luepker Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey Clin Chem 58 2012 930 935
145. T.J. Wang, K.C. Wollert, M.G. Larson, E. Coglianese, E.L. McCabe, S. Cheng, J.E. Ho, M.G. Fradley, A. Ghorbani, V. Xanthakis, T. Kempf, E.J. Benjamin, D. Levy, R.S. Vasan, and J.L. Januzzi Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study Circulation 126 2012 1596 1604
146. J.E. Ho, S.J. Hwang, K.C. Wollert, M.G. Larson, S. Cheng, T. Kempf, R.S. Vasan, J.L. Januzzi, T.J. Wang, and C.S. Fox Biomarkers of cardiovascular stress and incident chronic kidney disease Clin Chem 59 2013 1613 1620
147. J.E. Ho, W.Y. Chen, M.H. Chen, M.G. Larson, E.L. McCabe, S. Cheng, A. Ghorbani, E. Coglianese, V. Emilsson, A.D. Johnson, S. Walter, N. Franceschini, C.J. O'Donnell CARDIoGRAM Consortium CHARGE Inflammation Working Group A. Dehghan, C. Lu, D. Levy, C. Newton-Cheh CHARGE Heart Failure Working Group H. Lin, J.F. Felix, E.R. Schreiter, R.S. Vasan, J.L. Januzzi, R.T. Lee, and T.J. Wang Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling J Clin Invest 123 2013 4208 4218
148. V. Xanthakis, M.G. Larson, K.C. Wollert, J. Aragam, S. Cheng, J. Ho, E. Coglianese, D. Levy, W.S. Colucci, G. Michael Felker, E.J. Benjamin, J.L. Januzzi, T.J. Wang, and R.S. Vasan Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening J Am Heart Assoc 2 2013 e000399
149. M. Rienstra, X. Yin, M.G. Larson, J.D. Fontes, J.W. Magnani, D.D. McManus, E.L. McCabe, E.E. Coglianese, M. Amponsah, J.E. Ho, J.L. Januzzi Jr., K.C. Wollert, M.G. Fradley, R.S. Vasan, P.T. Ellinor, T.J. Wang, and E.J. Benjamin Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation Am Heart J 167 2014 109 115
150. J. Lu, J.V. Snider, and D.G. Grenache Establishment of reference intervals for soluble ST2 from a United States population Clin Chim Acta 411 2010 1825 1826
151. S. Tominaga A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor FEBS Lett 258 1989 301 304
152. A.K. Werenskiold, S. Hoffmann, and R. Klemenz Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts Mol Cell Biol 9 1989 5207 5214
153. J. Schmitz, A. Owyang, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, D.M. Gorman, J.F. Bazan, and R.A. Kastelein IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines Immunity 23 2005 479 490
154. S. Demyanets, C. Kaun, R. Pentz, K.A. Krychtiuk, S. Rauscher, S. Pfaffenberger, A. Zuckermann, A. Aliabadi, M. Gröger, G. Maurer, K. Huber, and J. Wojta Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature J Mol Cell Cardiol 60 2013 16 26
155. B. Dieplinger, M. Egger, W. Poelz, M. Haltmayer, and T. Mueller Long-term stability of soluble ST2 in frozen plasma samples Clin Biochem 43 2010 1169 1170
156. A.H. Wu, F. Wians, and A. Jaffe Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results Am Heart J 165 2013 995 999
157. T. Mueller, M. Zimmermann, B. Dieplinger, H.J. Ankersmit, and M. Haltmayer Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay Clin Chim Acta 413 2012 1493 1494
158. B. Dieplinger, M. Egger, W. Poelz, C. Gabriel, M. Haltmayer, and T. Mueller Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females Clin Chem Lab Med 49 2011 1515 1518